Product Information
NEVIRAPINE 200 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.1472 per EA under NDC 33342000409. Its NADAC has been published 156 times since Jul 15, 2020.
FDA first approved this application on Jan 14, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342000409
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NEVIRAPINEApproval Type
Generic (ANDA)
FDA Application
ANDA090688FDA Approved
1/14/2019
TE Code
AB
On Market Since
1/28/2019
Pharmacological Classes
Price Statistics
The NADAC for NEVIRAPINE 200 MG TABLET has been published 156 times since Jul 15, 2020, and over the history we have for it it has risen 6.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1472 per EA |
|---|---|
| All-time high | $0.1538 (Apr 10, 2024) |
| All-time low | $0.1122 (Jul 17, 2024) |
| 52-week high | $0.1528 |
| 52-week low | $0.1332 |
| Median price | $0.1332 |
| Average price | $0.1346 |
| Largest weekly change | -15.0% (Apr 17, 2024) |
| Weeks tracked | 156 |
| Tracking since | Jul 15, 2020 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Nevirapine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEVIRAPINE 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NEVIRAPINE 200 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $0.1472 per EA (NDC 33342000409), effective Sep 30, 2026.
How has the price of NEVIRAPINE 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for NEVIRAPINE 200 MG TABLET has risen 6.2%. It has been tracked across 156 weekly CMS publications since Jul 15, 2020.
What are the highest and lowest recorded NADAC prices for NEVIRAPINE 200 MG TABLET?
Since Jul 15, 2020, the NADAC for NEVIRAPINE 200 MG TABLET has ranged from a low of $0.1122 (Jul 17, 2024) to a high of $0.1538 (Apr 10, 2024), with a median of $0.1332 per EA.
Are there cheaper alternatives to NEVIRAPINE 200 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NEVIRAPINE 200 MG TABLET, is $0.1314 per EA — about 11% below NEVIRAPINE 200 MG TABLET.
Who manufactures NEVIRAPINE 200 MG TABLET?
NEVIRAPINE 200 MG TABLET (NDC 33342000409) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.